STRUCTURED THERAPY INTERRUPTION (STI) AND DECEPTIVE IMPRINTING

REFERENCES

• J., Salk. Prospects for the control of AIDS by immunizing seropositive individuals. Nature. 327: 473–476, 1987
   PubMed Web of Science ®Google Scholar
• C. P., Locher, R. M., Grant, E. A., Collisson, G., Reyes-Teran, T., Elbeik, J. O., Kahn, J. A., Levy. Antibody and cellular immune responses in breakthrough infection subjects after HIV type 1 glycoprotein 120 vaccination. AIDS Res. Hum. Retrovir.. 71: 1685–1659, 1999
   Google Scholar
• H., Kohler, P. L., Nara, S., Muller. Deceptive imprinting in the immune response to HIV-1 infection. Immunol. Today. 15: 475–478, 1994, [CSA], [CROSSREF]
   PubMedGoogle Scholar
• F., de St., Groth. The neutralization of viruses. Adv. Virus Res.. 9: 1–34, 1962
   Google Scholar
• V., Jubault, J., Pacanowski, C., Rabian, J. P., Viard. Interruption of prophylaxis for major opportunistic infections in HIV-infected patients receiving triple combination antiretroviral therapy. Ann Med. Interne (Paris). 151: 163–168, 2000
   Google Scholar
• F., Lori, D., Zinn, G., Varga, R., Maserati, E., Seminari, J., Timpone, N., Miller, R., Pal, P., Markham, J., Lisziewicz. Intermittent drug therapy increases the time to HIV rebound in humans and induces the control of SIV after treatment interruption in monkeys. Conf. Retroviruses. Opportunistic Infect.. 4: 206, 1999
   Google Scholar
• A. U., Neumann, R., Tubiana, V., Calvez, C., Robert, B., Autran, C., Katlama. Multi-phasic HIV decline following triple drug antiviral therapy is correlated with viral rebound dynamics. Conf. Retroviruses Opportunistic Infect.. 5: 176, (abstract no. 517). 1998
   Google Scholar
• J., Lisziewicz, E., Rosenberg, J., Lieberman, H., Jessen, L., Lopalco. Siliciano control of HIV despite the discontinuation of antiretroviral therapy [letter]. N. Engl. J. Med.. 340: 1683–1684, 1999, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• F., Lori, M. G., Lewis, J., Xu, G., Varga, D. E., ZinnJr, C., Crabbs, W., Wagner, J., Greenhouse, P., Silvera, J., Yalley-Ogunro, C., Tinelli, J., Lisziewicz. Control of SIV rebound through structured treatment interruptions during early infection. Science. 290: 1591–1593, 2000, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• F., Lori, D., Zinn, G., Varga, R., Maserati, E., Seminari, F., Timpone, N., Miller, R., Pal, P., Markham, J., Lisziewicz. Intermittent drug therapy increases the time to HIV rebound in humans and induces the control of SIV after treatment interruption in monkeys. Conf. Retroviruses Opportunistic Infect.. 4: 206, (abstract no. LB5). 1999
   Google Scholar
• D. C., Douek, R. D., McFarland, P. H., Keiser, E. A., Gage, J. M., Massey, B. F., Haynes, M. A., Polis, A. T., Haase, M. B., Feinberg, J. L., Sullivan, B. D., Jamieson, J. A., Zack, L. J., Picker, R. A., Koup. Changes in thymic function with age and during the treatment of HIV infection. Nature. 396: 690–695, 1998, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• J. E., Schmitz, M. J., Kuroda, S., Santra, V. G., Sasseville, M. A., Simon, M. A., Lifton, P., Racz, K., Tenner-Racz, M., Dalesandro, B. J., Scallon, J., Ghrayeb, M. A., Forman, D. C., Montefiori, E. P., Rieber, N. L., Letvin, K. A., Reimann. Control of viremia in simian immunodeficiency virus infection by CD8 +  lymphocytes. Science. 283: 857–860, 1999, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• H., Jaeger. et al.. Drug holidays (DH): Impact on VL, CD4 +  cells and clinical outcome in HIV+ patients. Durban AIDS Conf.. South Africa, July 9–14, 2000, WePeB4207.
   Google Scholar
• A Randomized Study of a Prescribed 4-Month Structured Treatment Interruption (STI) Followed by Initiation of a New Antiretroviral Regimen Versus Immediate Initiation of a New Antiretroviral Regimen in HIV-Infected Patients with Multidrug Resistant (MDR) Virus. Protocol ID Numbers (clinical trial identifier): NIAID CPCRA 064
   Google Scholar
• B. D., Walker, E. S., Rosenberg. Containing HIV after infection. Nat. Med.. 6: 1094–1095, 2000, [CSA], [CROSSREF]
   Google Scholar
• E. S., Rosenberg, M., Altfeld, S. H., Poon, M. N., Phillips, B. M., Wilkes, R. L., Eldridge, G. K., Robbins, R. T., D'Aquila, P. J., Goulder, B. D., Walker. Immune control of HIV-1 after early treatment of acute infection. Nature. 407: 523–526, 2000, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Daniel C., Douek, Jason M., Benchley, Michael R., Betts, David R., Ambrozak, Brenna J., Hill, Yukari, Okamoto, Joseph P., Casazza, Janaki, Kuruppu, Kevin, Kunstman, Steven, Wolinsky, Zvi, Grossman, Mark, Dybul, Annette, Oxenius, David A., Price, Mark, Connors, Richard A., Koup. HIV preferentially infects HIV-specific CD4  +   + T cells. Nature. 417: 95–98, 2002, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• S., Muller, D. H., Margolin, P. L., Nara, W. G., Alvord, H., Kohler. Stimulation of HIV-1- neutralizing antibodies in simian HIV-IIIB-infected macaques. Proc. Natl. Acad. Sci. USA. 95: 276–281, 1998
   Google Scholar
• T., Wrin, L., Crawford, L., Sawywer, P., Weber, H. W., Sheppard, C. V., Hansen. Neutralizing antibody response to autologous islolates of HIV. J. AIDS. 7: 219–221, 1994
   Google Scholar
• H., Cosenza, H., Kohler. Specific suppression of the antibody response by antibodies to receptors. Proc. Natl. Acad. Sci. USA. 69: 2701, 1972
   Google Scholar
• D. S., Strayer, H., Cosenza, W. M. F., Lee, D. A., Rowley, H., Kohler. Neonatal tolerance induced by antibody against antigen-specific receptor. Science. 186: 649, 1974
   Google Scholar
• A.Augustin, H., Cosenza. Expression of new idiotypes following neonatal idiotype suppression of a dominant clone. Eur. J. Immunol.. 6: 497–501, 1976
   PubMed Web of Science ®Google Scholar
• D. R., Kaplan, J., Quintans. Alteration of clonal profile I. Effect of sublethal irradiation on the response to phosphorylcholine in BALB/c mice. J. Exp. Med.. 148: 987–995, 1978, [CROSSREF]
   Google Scholar
• S., Muller, H.-T., Wang, S., Kaveri, S., Chattoppadhyay, H., Kohler. Generation and specificity of monoclonal anti-idiotypic antibodies against human HIV-specific antibodies. J. Immunol.. 147: 933–941, 1991
   PubMedGoogle Scholar
• H. T., Wang, S., Muller, S., Zolla-Pazner, H., Kohler. Human monoclonal and polyclonal anti-human immunodeficiency virus-1 antibodies share a common clonotypic specificity. Eur. J. Immunol.. 22: 1749–1755, 1992, [CSA]
   PubMedGoogle Scholar
• H., Kohler, S., Müller, P. L., Nara. Why AIDS vaccines that induce humoral immunity may not work. The Immunologist. 3: 32–34, 1995, [CSA]
   Google Scholar
• H., Kohler, S., Muller, M., Schiffer, P. L., Nara. Few clues for AIDS vaccines from structural data on gp120 and its receptors and antibodies. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 20: 315–316, 1999, [CSA]
   Google Scholar
• M., Altfeld, T. M., Allen, X. G., Yu, M. N., Johnston, D., Agrawal, B. T., Korber, D. C., Montefiori, D. H., O'Connor, B. T., Davis, P. K., Lee, E. L., Maier, J., Harlow, P. J., Goulder, C., Brander, E. S., Rosenberg, B. D., Walker. HIV-1 superinfection despite broad CD8 +  T-cell responses containing replication of the primary virus. Nature. 420: 434–438, 2002, [CROSSREF]
   PubMed Web of Science ®Google Scholar